Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma.

ABSTRACT: Multiple myeloma remains an incurable malignancy of plasma cells. Novel therapies, notably proteasome inhibitors and immunomodulatory drugs, have improved the survival of multiple myeloma patients; however, patients either present with, or develop resistance to, these therapies. Resistance to traditional chemotherapeutic agents can be caused by cellular drug efflux via adenosine triphosphate (ATP)-binding cassette (ABC) transporters, but it is still not clear whether these transporters mediate resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma. Solute carrier (SLC) transporters also play a role in cancer drug resistance due to changes in cell homeostasis caused by their abnormal expression and changes in the solutes they transport. In this review, we evaluat

SUBMITTER: Mynott RL 

PROVIDER: S-EPMC8204322 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature